Results 121 to 130 of about 32,704 (143)

A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain

Science immunology, 2020
A glycan-modified RSV nanoparticle vaccine displaying multimeric pre-F protein focuses antibody responses on neutralizing epitopes. Sharpening the focus of anti-RSV antibodies Respiratory syncytial virus (RSV) is a paramyxovirus that infects lung ...
K. Swanson, Jennifer N. Rainho-Tomko, Zachary P. Williams, Lilibeth Lanza, Michael Peredelchuk, Michael Kishko, V. Pavot, Judith Alamares-Sapuay, Haritha Adhikarla, Sankalp Gupta, Sudha Chivukula, Scott Gallichan, Linong Zhang, Nicholas Jackson, H. Yoon, D. Edwards, Chih-Jen Wei, G. Nabel   +17 more
semanticscholar   +1 more source

DSCG Reduces RSV‐induced illness in RSV‐infected mice

Journal of Medical Virology, 2008
AbstractRespiratory syncytial virus (RSV) is one of the pathogens generally associated with the common cold, lower respiratory infection, and exacerbation of asthma. Disodium cromoglycate (DSCG) is a safe and widely used drug for the prevention of bronchial asthma and allergic rhinitis attacks.
Syuichi Mori, Koichi Hashimoto, R.S. Peebles, Mitsuaki Hosoya, Kei Ishibashi, Yukihiko Kawasaki, Tatsuo Suzutani, Ken Ishioka, Yuko Hashimoto, Mitsuru Munakata, Hisatoshi Kaneko   +10 more
openaire   +3 more sources

RSV and Influenza

2004
Clinical and experimental studies have demonstrated that the pathophysiology of RSV infection is largely due to host responses rather than cytopathic effects of the virus. Therefore the use of anti-inflammatory agents such as steroids appears to be an attractive therapeutic option.
Mike Sharland, Birgit von Hoersten
openaire   +3 more sources

A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

Science Translational Medicine, 2017
Development of a highly potent anti-RSV monoclonal antibody with extended half-life intended to be used as RSV prophylaxis for all infants. Pan-RSV prophylaxis The common respiratory syncytial virus (RSV) can progress to a very dangerous lower ...
Qing Zhu, J. McLellan, N. Kallewaard, N. Ulbrandt, S. Palaszynski, Jing Zhang, B. Moldt, Anis A. Khan, Catherine Svabek, Josephine M. McAuliffe, D. Wrapp, N. Patel, Kimberly E. Cook, Bettina Richter, P. Ryan, A. Q. Yuan, J. Suzich   +16 more
semanticscholar   +1 more source

RSV prophylaxis in premature infants

Minerva Pediatrica, 2018
Infants born prematurely before 37 weeks of gestational age (GA) have particular anatomical, immunological and metabolic characteristics that predispose them, even in the absence of diseases at birth, to severe morbidity. Respiratory syncytial virus (RSV) is the leading cause of hospitalization for lower respiratory tract infections (LRTI) in the first
Del Vecchio, Antonio, Franco, Caterina, Del Vecchio, Karin, UMBALDO, ANGELA, Capasso, Letizia, Raimondi, Francesco   +5 more
openaire   +3 more sources

Treating RSV in the immunocompromised

Nursing Standard, 1993
Tribavirin may be a useful treatment for respiratory syncytial virus (RSV) in people who are immunocompromised.
openaire   +2 more sources

COVID and RSV

Don't Forget The Bubbles, 2021
Laura Riddick, Andrew Tagg, Damian Roland   +2 more
openaire   +2 more sources

Past, present and future of RSV and PIV vaccines and anti-RSV antibodies for the protection of humans against RSV

Expert Opinion on Therapeutic Patents, 2007
The human respiratory syncytial virus (RSV) is a human pathogen that infects infants, children under 2 years of age and elderly people, causing a lower respiratory tract infection, while evading the host's adaptive immune response. This review summarises the efforts to develop a safe vaccine and synthetic antibodies for immunisation of infants and ...
openaire   +2 more sources

Immunoprophylaxis of RSV Infection: Advancing from RSV-IGIV to Palivizumab and Motavizumab

2008
Antibodies mediate humoral immune responses and play key roles in the defense of viral infection by the recognition, neutralization, and elimination of viruses from the circulation. For the prevention of respiratory syncytial virus (RSV) infection, the natural immune response to RSV from pooled human plasma has been harvested and successfully developed
Herren Wu, P. A. Kiener, D. S. Pfarr, G. A. Losonsky   +3 more
openaire   +3 more sources

RSV and the infant

Home Care Provider, 2000
openaire   +5 more sources